Clinical trials: Antineoplastics Toxicity
Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity
Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors
RATIONALE: Learning whether temozolomide changes semen or sperm in patients with brain tumors may help doctors learn about the long-term effects of treatment and plan the best treatment.
- Conditions
- Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity, Infertility
- Trial name
- NCT00499798
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Chemotherapeutic Agent Toxicity, Neurotoxicity
Acute Pain Caused by Paclitaxel in Patients With Cancer
RATIONALE: Gathering information over time from patients receiving paclitaxel for cancer may help doctors learn more about pain caused by paclitaxel and plan the best treatment.
- Conditions
- Chemotherapeutic Agent Toxicity, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00860041
- Testing
- pain questionnaires
- Where
- 279 sites in United States
- Volunteers
- 306 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chemotherapeutic Agent Toxicity, Neutropenia
G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy
RATIONALE: Colony-stimulating factors, such as G-CSF, may increase the number of white blood cells found in bone marrow or peripheral blood and may prevent persistent neutropenia in patients receiving chemotherapy.
- Conditions
- Chemotherapeutic Agent Toxicity, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00770172
- Testing
- filgrastim
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Centre Francois Baclesse
Heart Failure, Cardiotoxicity
The STOP-MED CTRCD Trial
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients.
- Conditions
- Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity
- Trial name
- STOP-MED CTRCD (NCT06183437)
- Testing
- Stopping Heart Failure Medication(s)
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 335 people
- Sponsor
- Dinesh Thavendiranathan
Chemotherapeutic Agent Toxicity, Mucositis
Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy
This randomized phase II trial is studying how well selenomethionine (SLM) works in reducing mucositis in patients with locally advanced head and neck cancer who are receiving cisplatin and radiation therapy.
- Conditions
- Chemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01682031
- Testing
- selenomethionine, cisplatin, radiation therapy
- Where
- 2 sites in United States, New Zealand
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Chemotherapeutic Agent Toxicity, Neurotoxicity
Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy
RATIONALE: Electronic stimulation using a MC5-A Scrambler may help relieve pain in patients who develop peripheral neuropathy while undergoing chemotherapy treatments for cancer.
- Conditions
- Chemotherapeutic Agent Toxicity, Neurotoxicity, Pain, Peripheral Neuropathy
- Trial name
- NCT00952848
- Testing
- questionnaire administration, Sensory Neuropathy Scale instrument, Quality of Life instrument
- Volunteers
- 18 people
- Sponsor
- Virginia Commonwealth University
Dermatologic Complications, Palmar-plantar Erythrodysesthesia
Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer
RATIONALE: Pyridoxine may help prevent hand-foot syndrome caused by capecitabine in patients with cancer. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome in patients with…
- Conditions
- Dermatologic Complications, Palmar-plantar Erythrodysesthesia, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00486213
- Testing
- pyridoxine hydrochloride
- Where
- Singapore
- Volunteers
- 210 people
- Sponsor
- National Cancer Centre, Singapore
Chemotherapeutic Agent Toxicity, Sarcoma
CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide
RATIONALE: Studying the genes expressed in samples of blood from young patients with cancer treated with ifosfamide may help doctors identify risk factors for kidney damage.
- Conditions
- Chemotherapeutic Agent Toxicity, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00514345
- Testing
- gene expression analysis, polymorphism analysis, management of therapy complications
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 300 people
- Sponsor
- Children's Cancer and Leukaemia Group
Urologic Neoplasms, Urogenital Neoplasms
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
This is a non-blinded phase 2 trial in Stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab to assess whether bladder preservation after dual immunotherapy would be a viable treatment…
- Conditions
- Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Neoplasms
- Trial name
- TURANDORELA (NCT06237920)
- Testing
- Nivolumab, Relatlimab
- Where
- 9 sites in Netherlands
- Volunteers
- 90 people
- Sponsor
- The Netherlands Cancer Institute
Chemotherapeutic Agent Toxicity, Pancreatic Cancer
Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chemotherapeutic Agent Toxicity, Pancreatic Cancer, Thromboembolism
- Trial name
- PAM07 (NCT00662688)
- Testing
- daltéparine, Chemotherapy at the investigator's discretion
- Where
- 6 sites in France
- Volunteers
- 42 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Chemotherapeutic Agent Toxicity, Renal Toxicity
Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Chemotherapeutic Agent Toxicity, Renal Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00695032
- Testing
- cisplatin, ifosfamide, laboratory biomarker analysis
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Institut Claudius Regaud
Chemotherapy-induced Peripheral Neuropathy, Chemotherapeutic Toxicity
Cryotherapy vs. Cryocompression for Preventing Chemotherapy-induced-peripheral-neuropathy in Women Undergoing Chemotherapy
This study's aim is to show a benefit of Cryocompression (cooling hands with additional compression of the hands) in comparison to Cryotherapy (just cooling hands) in female cancer patients (with gynecological cancer) receiving…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Chemotherapeutic Toxicity, Chemotherapeutic Agent Toxicity
- Trial name
- NCT04632797
- Testing
- Hilotherm Chemo Care
- Where
- Austria
- Volunteers
- 196 people
- Sponsor
- Medical University Innsbruck
Chemotherapeutic Agent Toxicity, Head and Neck Cancer
Randomized Amifostine For SCCHN
This research study is studying a drug called Amifostine as a treatment for squamous cell carcinoma in the head and/or neck area.
- Conditions
- Chemotherapeutic Agent Toxicity, Head and Neck Cancer, Mucositis, Radiation Toxicity
- Trial name
- NCT00095927
- Testing
- Amifostine, Carboplatin, Paclitaxel
- Where
- 9 sites in United States
- Volunteers
- 58 people
- Sponsor
- Dana-Farber Cancer Institute
Chemotherapeutic Toxicity, Chemotherapeutic Agent Toxicity
Diminish Chemotherapy Related Side Effects Through Patient Education
Currently, there is a lack of patient education materials regarding cytotoxic chemotherapy side effects, research supported treatments, and the utilization of CAM by cancer patients at Penn State Cancer Institute.
- Conditions
- Chemotherapeutic Toxicity, Chemotherapeutic Agent Toxicity, Chemotherapy Effect
- Trial name
- D-CRSE (NCT04694794)
- Testing
- Educational Brochure
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Milton S. Hershey Medical Center
Neoplasms
Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines
The primary purpose of this study is to prospectively determine whether capecitabine and 5-FU-induced toxicity is preventable by dose reduction prior to start of the first administration in patients heterozygous or homozygous…
- Trial name
- NCT00838370
- Testing
- Capecitabine, 5-fluorouracil
- Where
- 3 sites in Netherlands
- Volunteers
- 22 people
- Sponsor
- The Netherlands Cancer Institute
Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them.
- Conditions
- Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Lymphoma, Neurotoxicity
- Trial name
- NCT01399372
- Testing
- Rituximab, Cytarabine, Methotrexate
- Where
- 45 sites in United States, Israel
- Volunteers
- 91 people
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Squamous Cell Carcinoma, Locally Advanced Rectal Cancer
GALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients
GALENOS 1 is a prospective observational study designed to explore longitudinal changes in nutritional status and body composition in patients with head and neck squamous cell carcinoma, locally advanced rectal cancer, and lung…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Locally Advanced Rectal Cancer, Lung Cancer
- Trial name
- GALENOS 1 (NCT07511413)
- Where
- Italy
- Volunteers
- 110 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Dysphagia, Head and Neck Cancer
Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Dysphagia, Head and Neck Cancer, Mucositis, Xerostomia
- Trial name
- NCT00503776
- Testing
- exercise intervention, amifostine trihydrate, therapeutic dietary intervention
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Nutrition Aspect of Cancer, Sarcopenia
Malnutrition and Sarcopenia Screening in Chemotherapy Patients
The study will include approximately 150 adult outpatients diagnosed with solid tumors who are currently receiving chemotherapy.
- Conditions
- Nutrition Aspect of Cancer, Sarcopenia, Chemotherapeutic Agent Toxicity
- Trial name
- NCT07163286
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Çanakkale Onsekiz Mart University
Kidney Injury, Antineoplastics Toxicity
Immune Checkpoint Inhibitors Nephrotoxicity
In recent years, immunotherapy has been postulated as one of the most effective strategy in the fight against cancer. The greatest success in this field has been achieved through the inhibition of molecules involved in the brake…
- Trial name
- NCT04902846
- Testing
- Early kidney damage biomarkers, Predisposition to kidney injury biomarkers
- Where
- 2 sites in Spain
- Volunteers
- 220 people
- Sponsor
- R. Laura Vicente Vicente